Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:46:40.533Z.
Calculation as of: 2026-10-06T12:46:40.533Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6da64a8b1a2a274dcb8686c6d20e6c80d542b1d2a14b58c5ff35188fa74041c0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$6.10M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.03M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.10M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | N/A | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.34M | N/A | 1.29% | 1.35% | 1.32% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.74M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | N/A | 3.10% | 3.10% | 1.95% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
